Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Apyx Medical (APYX) Other Non-Current Liabilities (2016 - 2026)

Apyx Medical filings provide 14 years of Other Non-Current Liabilities readings, the most recent being $347000.0 for Q4 2025.

  • On a quarterly basis, Other Non-Current Liabilities rose 33.98% to $347000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $347000.0, a 33.98% increase, with the full-year FY2025 number at $347000.0, up 33.98% from a year prior.
  • Other Non-Current Liabilities hit $347000.0 in Q4 2025 for Apyx Medical, up from $293000.0 in the prior quarter.
  • In the past five years, Other Non-Current Liabilities ranged from a high of $347000.0 in Q4 2025 to a low of $133000.0 in Q3 2022.
  • Median Other Non-Current Liabilities over the past 5 years was $185000.0 (2023), compared with a mean of $200100.0.
  • Biggest five-year swings in Other Non-Current Liabilities: plummeted 81.05% in 2021 and later soared 52.08% in 2025.
  • Apyx Medical's Other Non-Current Liabilities stood at $166000.0 in 2021, then grew by 9.04% to $181000.0 in 2022, then rose by 9.39% to $198000.0 in 2023, then skyrocketed by 30.81% to $259000.0 in 2024, then skyrocketed by 33.98% to $347000.0 in 2025.
  • The last three reported values for Other Non-Current Liabilities were $347000.0 (Q4 2025), $293000.0 (Q3 2025), and $292000.0 (Q2 2025) per Business Quant data.